Atara Biotherapeutics, Inc. (0HIY.L)
0HIY.L Stock Price Chart
Explore Atara Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0HIY.L price movements and trends.
0HIY.L Company Profile
Discover essential business fundamentals and corporate details for Atara Biotherapeutics, Inc. (0HIY.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
153.00
Website
https://www.atarabio.comCEO
Anhco Nguyen
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
0HIY.L Financial Timeline
Browse a chronological timeline of Atara Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 5 Mar 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 11 Aug 2025
Revenue estimate is $4.23M.
Earnings released on 15 May 2025
EPS came in at $3.50 surpassing the estimated -$1.98 by +276.77%, while revenue for the quarter reached $98.10M, beating expectations by +2.18K%.
Earnings released on 7 Mar 2025
EPS came in at -$1.19 surpassing the estimated -$2.86 by +58.50%, while revenue for the quarter reached $32.75M, beating expectations by +59.12%.
Earnings released on 13 Nov 2024
EPS came in at -$2.93 falling short of the estimated -$1.89 by -55.23%, while revenue for the quarter reached $40.19M, beating expectations by +21.44%.
Earnings released on 13 Aug 2024
EPS came in at -$3.10 falling short of the estimated -$2.24 by -38.56%, while revenue for the quarter reached $28.64M, missing expectations by -22.79%.
Stock split effective on 20 Jun 2024
Shares were split 1:25, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at -$5.65 surpassing the estimated -$6.42 by +12.01%, while revenue for the quarter reached $27.36M, beating expectations by +10.80%.
Earnings released on 28 Mar 2024
EPS came in at -$13.98 falling short of the estimated -$11.13 by -25.62%, while revenue for the quarter reached $4.25M, beating expectations by +65.96%.
Earnings released on 1 Nov 2023
EPS came in at -$16.40 falling short of the estimated -$15.57 by -5.33%, while revenue for the quarter reached $2.14M, missing expectations by -57.99%.
Earnings released on 9 Aug 2023
EPS came in at -$0.68 surpassing the estimated -$16.40 by +95.88%, while revenue for the quarter reached $957.00K, missing expectations by -78.05%.
Earnings released on 9 May 2023
EPS came in at -$0.72 surpassing the estimated -$9.27 by +92.24%, while revenue for the quarter reached $1.23M, missing expectations by -96.17%.
Earnings released on 9 Feb 2023
EPS came in at -$0.72 surpassing the estimated -$12.99 by +94.44%, while revenue for the quarter reached $221.00K, missing expectations by -99.35%.
Earnings released on 30 Sept 2022
EPS came in at -$0.82 surpassing the estimated -$18.64 by +95.59%, while revenue for the quarter reached $4.46M, missing expectations by -13.14%.
Earnings released on 30 Jun 2022
EPS came in at $0.18 surpassing the estimated -$19.90 by +100.91%, while revenue for the quarter reached $51.58M, beating expectations by +654.35%.
Earnings released on 31 Mar 2022
EPS came in at -$0.87 surpassing the estimated -$0.93 by +6.17%, while revenue for the quarter reached $7.31M, beating expectations by +26.38%.
Earnings released on 31 Dec 2021
EPS came in at -$0.96, while revenue for the quarter reached $7.55M.
Earnings released on 30 Sept 2021
EPS came in at -$0.90 falling short of the estimated -$0.69 by -30.37%, while revenue for the quarter reached $5.37M, missing expectations by -82.88%.
Earnings released on 30 Jun 2021
EPS came in at -$0.91, while revenue for the quarter reached $3.87M.
Earnings released on 31 Mar 2021
EPS came in at -$0.86, while revenue for the quarter reached $3.55M.
Earnings released on 31 Dec 2020
EPS came in at -$0.95, while revenue for the quarter reached $358.19M.
Earnings released on 30 Sept 2020
EPS came in at -$0.92.
0HIY.L Stock Performance
Access detailed 0HIY.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.